+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Syndromic Multiplex Diagnostic Markets with COVID-19 Impacts. Strategies and Trends, Forecasts by Syndrome (Respiratory, Sepsis, GI Etc.), by Country, with Market Analysis, Executive Guides and Customization 2021 - 2025

  • ID: 5185319
  • Report
  • October 2020
  • Region: Global
  • 413 Pages
  • Howe Sound Research
1 of 4
The COVID Pandemic Drives Syndromic Diagnostics into Hypergrowth! Market Explodes Overnight.

FEATURED COMPANIES

  • Accelerate Diagnostics
  • Biocartis
  • Diasorin
  • Inflammatix
  • Mesa Biotech
  • Qiagen (Statdx)
  • MORE

How will COVID-19 affect Syndromic and Infectious Disease Diagnostics? The COVID pandemic is ushering in a new world of infectious disease diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician’s Office or even the Home?

Syndromic testing is proving itself in the market. Players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out to 2024. In a special section the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel-based ordering of infectious disease tests.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Accelerate Diagnostics
  • Biocartis
  • Diasorin
  • Inflammatix
  • Mesa Biotech
  • Qiagen (Statdx)
  • MORE

Market Guides

  • Situation Analysis & COVID Impact Overview
  • Guide for Executives and Marketing Staff
  • Guide for Investment Analysts and Management Consultants
  • Market Shares of Leading Companies - Table and Chart

1. Introduction and Market Definition
1.1 What are Syndromic Multiplex Tests?
1.2 Syndromic Testing - the quiet revolution in diagnostics
1.2.1 Syndromic Testing - more than Panels
1.3 Market Definition
1.3.1 Multiplex Market Size
1.3.2 Currency
1.3.3 Years
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases - Guide to the Pathogens
2.0 The Coronavirus
2.0.1 Severe acute respiratory syndrome (SARS)
2.0.2 Middle East respiratory syndrome (MERS)
2.0.3 COVID-19. The SARS CoV 2 Virus
2.0.3.1 Signs and symptoms
2.0.3.2 Transmission
2.0.3.3 Diagnosis
2.0.3.4 Prevention
2.0.3.5 Management
2.0.3.6 Prognosis
2.1 HIV - Human Immunodeficiency Virus (AIDS)
2.1.1 Virology
2.1.1.1 Classification
2.1.1.2 Structure and genome
2.1.1.3 Tropism
2.1.1.4 Replication cycle
2.1.1.5 Genetic variability
2.1.2 Diagnosis
2.1.3 Testing
2.1.3.1 Antibody tests
2.1.3.2 Point of Care Tests (POCT)
2.1.3.4 Antigen Tests
2.1.3.5 Nucleic acid-based tests (NAT)
2.1.3.6 Other tests used in HIV treatment
2.2 HBV - Hepatitis B
2.2.1 Virology
2.2.1.1 Genome
2.2.1.2 Pathogenesis
2.2.1.3 Hepatitis B virus replication
2.2.1.4 Serotypes and genotypes
2.2.2 Mechanisms
2.2.3 Diagnosis
2.2.4 Market Opportunity Analysis
2.3 HCV - Hepatitis C
2.3.1 Taxonomy
2.3.2.1 Structure
2.3.2.2 Genome
2.3.3 Molecular biology
2.3.4 Replication
2.3.5 Genotypes
2.3.5.1 Clinical importance
2.3.6 Market Opportunity Analysis
2.4 HPV - Human papillomavirus
2.4.1 Virology
2.4.1.1 E6/E7 proteins
2.4.1.2 Role in cancer
2.4.1.3 E2 research
2.4.1.4 Latency period
2.4.1.5 Clearance
2.4.2 Diagnosis
2.4.2.1 Cervical testing
2.4.2.2 Oral testing
2.4.2.3 Testing men
2.4.2.4 Other testing
2.4.3 Market Opportunity Analysis
2.5 Influenza
2.5.1 Virology
2.5.1.1 Types of virus
2.5.1.2 Influenzavirus A
2.5.1.3 Influenzavirus B
2.5.1.4 Influenzavirus C
2.5.1.5 Structure, properties, and subtype nomenclature
2.5.1.6 Replication
2.5.2 Testing
2.5.2.1 Advantages/Disadvantages of Molecular Assays
2.5.3 Market Opportunity Analysis
2.6 CTGC - Chlamydia/Gonorhea
2.6.1 Gonorrhea
2.6.1.1 Diagnosis
2.6.1.2 Screening
2.6.2 Chlamydia
2.6.2.1 Diagnosis
2.6.2.2 Screening
2.6.3 Testing
2.6.3.1 Nucleic acid amplification tests (NAATs).
2.6.3.2 Performance of NAAT Tests
2.6.4 Market Opportunity Analysis
2.7 Tuberculosis
2.7.1 Mycobacteria
2.7.2 Diagnosis
2.7.2.1 Active tuberculosis
2.7.2.2 Latent tuberculosis
2.7.3 Epidemiology
2.7.4 Molecular Diagnostic Tests
2.7.5 Market Opportunity Analysis
2.8 MRSA - Methicillin-resistant Staphylococcus aureus
2.8.1 Diagnosis
2.8.2 FDA Approved Molecular Tests
2.8.3 Market Opportunity Analysis
2.9 VRE - Vancomycin-resistant Enterococcus
2.9.1 FDA Approved MDx Tests for VRE
2.9.2 Market Opportunity Analysis
2.10 VRE - Vancomycin-resistant Enterococcus
2.9.1 FDA Approved MDx Tests for VRE
2.9.2 Market Opportunity Analysis

3. Industry Overview
3.1 Industry Participants
3.1.1 IVD Supplier
3.1.2 Independent lab specialized/esoteric
3.1.3 Independent lab national/regional
3.1.4 Independent lab analytical
3.1.5 Public National/regional lab
3.1.6 Hospital lab
3.1.7 Physician lab
3.1.8 Audit body
3.2 The Clinical Laboratory Market Segments
3.2.1 Traditional Market Segmentation
3.2.2 Laboratory Focus and Segmentation
3.2.3 Segmenting the Syndromic Testing Market
3.3 Industry Structure
3.3.1 Hospital Testing Share
3.3.2 Economies of Scale
3.3.2.1 Hospital vs. Central Lab
3.3.3 Physician Office Lab’s
3.3.4 Physician’s and POCT

4. Market Trends
4.1 Factors Driving Growth
4.1.1 Speed of Diagnosis
4.1.2 Effect of Syndromic Testing on Costs.
4.1.3 Point of Care Advantage.
4.1.4 Syndrome Testing, Accuracy and Diagnostic Risk
4.1.5 Single Visits
4.1.6 Improvement in Outcomes.
4.1.7 Impact of the COVID-19 Pandemic.
4.2 Factors Limiting Growth
4.2.1 Lower Prices
4.2.2 Administration/reimbursement
4.2.3 Infectious Disease is Declining But….
4.2.4 Wellness Hurts
4.2.5 Economic Growth improves Living Standards
4.2.6 Impact of the Pandemic Recession
4.3 Instrumentation and Automation
4.3.1 Instruments Key to Market Share
4.3.2 The Shrinking Machine
4.3.3 Syndrome Testing Moving to Big Instruments?
4.4 Diagnostic Technology Development
4.4.1 Comparing Syndrome and Targeted Testing
4.4.2 The Multiplex Paradigm Shift
4.4.2 The Sepsis Testing Market - Bellwether for Syndromics
4.4.3 The Single Visit and AntiMicrobial Resistance
4.4.4 Syndromics drives POCT adoption
4.4.5 A Big Future for PCR?

5. Syndromic Testing Recent Developments

  • Recent Developments - Importance and How to Use This Section
  • Importance of These Developments
  • How to Use This Section
  • Scanogen’s Portable Battery Operated Instrument for 90 Minute Multiplex Test
  • Qiagen sees NeuMoDx as Growth Vehicle
  • Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround
  • Roche, SpeeDx Partner to Expand Access to Antibiotic Resistance Tests
  • BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU
  • Infectious Disease Testing Firm Curative Acquires KorvaLabs
  • ChromaCode Raises Additional $10M
  • COVID-19 Patients Need Syndromic Testing
  • GenMark Diagnostics - New Respiratory Panel due in June
  • Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark
  • Exact Diagnostics launches respiratory panel control
  • bioMérieux submits enhanced BIOFIRE® BCID2 Panel to FDA
  • Nanomix Receives CE Mark for Diagnostic
  • Applied BioCode Applies to FDA for Syndromic Respiratory Panel
  • Expedeon AG and Sona Nanotech to Collaborate on Multiplex POC
  • QIAGEN’s New GI Panel Performance Assessed
  • McKesson to Distribute QIAstat-Dx Syndromic Testing Solution in USA
  • Applied BioCode Obtains FDA Clearance
  • Meridian Bioscience to Acquire GenePOC Inc
  • Curetis Introduces Rapid DNA Testing for Antibiotic Resistance
  • Qiagen gets FDA clearance for syndromic testing system
  • Entasis Therapeutics Signs Rapid Diagnostic Agreement with bioMérieux
  • Akonni Biosystems Submits Multiplex Diagnostics System to FDA
  • Ador Diagnostic to receive $30M in Funding for 100-Plex PoC
  • SAW Diagnostics Receives Funding for Commercialisation of PoC Platform
  • QuantuMDx and Molbio announce MoU
  • Immunexpress Wins $745K Contract for Rapid Sepsis Assay
  • Mobidiag Inks European, Middle Eastern Distribution Deals
  • BIOFIRE® FILMARRAY® System chosen for Phase 3 clinical trial

5.1 Profiles of Key Syndromic Testing Companies

  • Abbott Diagnostics (Alere)
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akkoni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Atlas Genetics
  • Aus Diagnostics
  • BD Diagnostics
  • Biocartis
  • BioFire Diagnostics
  • bioMérieux
  • Bio-Rad Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Cue Health
  • Curetis
  • Diagenode Diagnostics
  • Diasorin
  • Expedeon
  • Fusion Genomics
  • GenePOC Diagnostics
  • Genetic Signatures
  • GenMark Dx
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexigene
  • Luminex
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Novacyt
  • Oxford Nanopore
  • Panagene
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Thermo Fisher
  • Veramarx
  • XCR Diagnostics

6. The Global Market for Syndromic Multiplex Diagnostics
6.1 Global Market Overview by Country
6.1.1 Table - Global Market by Country
6.1.2 Chart - Global Market by Country
6.2 Global Market by Syndrome - Overview
6.2.1 Table - Global Market by Syndrome
6.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
6.2.3 Chart - Global Market by Syndrome - Base Year
6.2.4 Chart - Global Market by Syndrome - End Year
6.2.5 Chart - Global Market by Syndrome - Share by Year
6.2.6 Chart - Global Market by Syndrome - Segments Growth
6.3 Global Market by Place - Overview
6.3.1 Table - Global Market by Place
6.3.2 Chart - Global Market by Place - Base/Final Year Comparison
6.3.3 Chart - Global Market by Place - Base Year
6.3.4 Chart - Global Market by Place - End Year
6.3.5 Chart - Global Market by Place - Share by Year
6.3.6 Chart - Global Market by Place - Segments Growth

7. Global Syndromic Multiplex Markets - By Syndrome
7.1 Respiratory
7.1.1 Table Respiratory - by Country
7.1.2 Chart - Respiratory Growth
7.2 Gastrointestinal
7.2.1 Table Gastrointestinal - by Country
7.2.2 Chart - Gastrointestinal Growth
7.3 Blood
7.3.1 Table Blood - by Country
7.3.2 Chart - Blood Growth
7.4 Meningitis/Encephalitis
7.4.1 Table Meningitis/Encephalitis - by Country
7.4.2 Chart - Meningitis/Encephalitis Growth
7.5 Sexually Transmitted Disease
7.5.1 Table Sexually Transmitted Disease - by Country
7.5.2 Chart - Sexually Transmitted Disease Growth
7.6 Other
7.6.1 Table Other - by Country
7.6.2 Chart - Other Growth

8. Global MDx Infectious Disease Markets - by Place
8.1 Hospital Lab
8.1.1 Table Hospital Lab - by Country
8.1.2 Chart - Hospital Lab Growth
8.2 Outpatient Lab
8.2.1 Table Outpatient Lab - by Country
8.2.2 Chart - Outpatient Lab Growth
8.3 POC
8.3.1 Table POC - by Country
8.3.2 Chart - POC Growth
8.4 Other Technology
8.4.1 Table Other - by Country
8.4.2 Chart - Other Growth

Appendices
I. United States Medicare System: 2020 Clinical Laboratory Fees Schedule
II. COVID-19 Approved Assays

List of Tables

Table 1 Market Share of Leading Companies
Table 2 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
Table 3 Characteristics of Coronavirus Pandemic Infections
Table 4 COVID-19 Symptoms
Table 5 Classification of HIV Species
Table 6 HBV Tests - CMS Codes & Prices
Table 7 HCV Tests - CMS Codes & Prices
Table 8 HPV Clearance Rates
Table 9 HPV Tests - CMS Codes & Prices
Table 10 HPV Tests, Technology, Types
Table 11 Types of Influenza Tests
Table 12 Influenza Tests - CMS Codes & Prices
Table 13 FDA Cleared Molecular Assays for Influenza
Table 14 FDA Cleared NAAT CTGC Tests
Table 15 CTGC NAAT Target Sequences and Possible False Reactions
Table 16 Influenza Tests - CMS Codes & Prices
Table 17 FDA Approved MDx Tests for Tuberculosis
Table 18 Tuberculosis Tests - CMS Codes & Prices
Table 19 FDA Approved Tests for MRSA
Table 20 MRSA Tests - CMS Codes & Prices
Table 21 FDA Approved Tests for VRE
Table 22 VRE Tests - CMS Codes & Prices
Table 23 FDA Approved Tests for VRE
Table 24 VRE Tests - CMS Codes & Prices
Table 25 Market Players by Type
Table 26 Clinical Laboratory Departments and Segments
Table 27 Laboratory Management Focus - Different Approaches
Table 28 Key Segmentation Variables Going Forward
Table 29 Possible Market Segments of Syndromic Multiplex Market
Table 30 Five Factors Driving Growth
Table 31 How SMT Improves Outcomes
Table 32 Four Factors Limiting Growth
Table 33 - Global Market by Region
Table 34 Global Market by Syndrome
Table 35 Global Market by Place
Table 36 Respiratory by Country
Table 37 Gastrointestinal by Country
Table 38 Blood by Country
Table 39 Meningitis/Encephalitis by Country
Table 40 Sexually Transmitted Disease by Country
Table 41 Other by Country
Table 42 Hospital Lab by Country
Table 43 Outpatient Lab by Country
Table 44 POC by Country
Table 45 Other by Country
Table 46 2020 Clinical Lab Fee Schedule
Table 47 COVID -19 Approved Assays

List of Figures

Figure 1 Market Share of Leading Companies Chart
Figure 2 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
Figure 3 Structure of Coronaviruses
Figure 4 HIV Virion
Figure 5 Diagram of the HIV Replication Cycle
Figure 6 The Structure of the HBV Virus
Figure 7 Hepatitis B Replication
Figure 8 Structure of the HCV Virus
Figure 9 HCV Replication Cycle
Figure 10 Structure of the Influenza Virion
Figure 11 Influenza Replication
Figure 12 Scanning Electron micrograph of Tuberculosis
Figure 13 Chart Death Rates and Infectious Disease Decline
Figure 14 Comparing Syndromic and Targeted Testing
Figure 15 The Multiplex Paradigm Shift
Figure 16 Global Market Share Chart
Figure 17 Global Market by Syndrome - Base vs. Final
Figure 18 Global Market by Syndrome Base Year
Figure 19 Global Market by Syndrome End Year
Figure 20 Syndrome Share by Year
Figure 21 Syndrome Segments Growth
Figure 22 Global Market by Place - Base vs. Final
Figure 23 Global Market by Place Base Year
Figure 24 Global Market by Place End Year
Figure 25 Place Share by Year
Figure 26 Place Segments Growth
Figure 27 Respiratory Growth
Figure 28 Gastrointestinal Diagnostics Growth
Figure 29 Blood Growth
Figure 30 Meningitis/Encephalitis Growth
Figure 31 Sexually Transmitted Disease Growth
Figure 32 Other Growth
Figure 33 Hospital Lab Growth
Figure 34 Outpatient Lab Growth
Figure 35 POC Growth
Figure 36 Other Growth

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Diagnostics (Alere)
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akkoni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Atlas Genetics
  • Aus Diagnostics
  • BD Diagnostics
  • Bio-Rad Laboratories
  • Biocartis
  • BioFire Diagnostics
  • bioMérieux
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Cue Health
  • Curetis
  • Diagenode Diagnostics
  • Diasorin
  • Expedeon
  • Fusion Genomics
  • GenePOC Diagnostics
  • Genetic Signatures
  • GenMark Dx
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexigene
  • Luminex
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Novacyt
  • Oxford Nanopore
  • Panagene
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Thermo Fisher
  • Veramarx
  • XCR Diagnostics
Note: Product cover images may vary from those shown
Adroll
adroll